53. シェーグレン症候群
[臨床試験数:234,薬物数:270(DrugBank:85),標的遺伝子数:49,標的パスウェイ数:174

Searched query = "Sjogren syndrome", "Sjögren syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-004476-30-PL
(EUCTR)
26/08/201620/07/2016A Study to Evaluate the Efficacy of RO5459072 in Participants With Primary Sjögren’s SyndromeA MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP PHASE 2A STUDY TO ASSESS THE EFFICACY OF RO5459072 IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME Primary Sjögren’s syndrome
MedDRA version: 20.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Cathepsin S inhibitor
Product Code: RO545-9072/F03
INN or Proposed INN: Not applicable
Other descriptive name: RO5459072
F. Hoffmann-La Roche LtdNULLNot RecruitingFemale: yes
Male: yes
70Phase 2Portugal;France;United States;Poland;Germany;United Kingdom
2EUCTR2015-004476-30-DE
(EUCTR)
18/07/201618/05/2016A Study to Evaluate the Efficacy of RO5459072 in Participants With Primary Sjögren’s SyndromeA MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP PHASE 2A STUDY TO ASSESS THE EFFICACY OF RO5459072 IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME Primary Sjögren’s syndrome
MedDRA version: 19.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Cathepsin S Inhibitor
Product Code: RO545-9072/F03
INN or Proposed INN: Not applicable
Other descriptive name: RO5459072
F. Hoffmann-La Roche LtdNULLNot RecruitingFemale: yes
Male: yes
70Phase 2Portugal;France;United States;Poland;Germany;Italy;United Kingdom
3NCT02701985
(ClinicalTrials.gov)
July 5, 20163/3/2016A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's SyndromeA Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients With Primary Sjogren's SyndromeSjogren's SyndromeDrug: Placebo;Drug: RO5459072Hoffmann-La RocheNULLCompleted18 Years75 YearsAll75Phase 2United States;France;Germany;Poland;Portugal;United Kingdom
4EUCTR2015-004476-30-FR
(EUCTR)
27/06/201604/09/2017A Study to Evaluate the Efficacy of RO5459072 in Participants With Primary Sjögren’s SyndromeA MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP PHASE 2A STUDY TO ASSESS THE EFFICACY OF RO5459072 IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME Primary Sjögren’s syndrome
MedDRA version: 20.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Cathepsin S
Product Code: RO545-9072/F03
INN or Proposed INN: Not applicable
Other descriptive name: RO5459072
F. Hoffmann-La Roche LtdNULLNot RecruitingFemale: yes
Male: yes
70Phase 2Portugal;United States;France;Poland;Germany;Italy;United Kingdom
5EUCTR2015-004476-30-GB
(EUCTR)
22/06/201616/03/2016A Study to Evaluate the Efficacy of RO5459072 in Participants With Primary Sjögren’s SyndromeA MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP PHASE 2A STUDY TO ASSESS THE EFFICACY OF RO5459072 IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME Primary Sjögren’s syndrome
MedDRA version: 19.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
F. Hoffmann-La Roche LtdNULLNot Recruiting Female: yes
Male: yes
70Phase 2Portugal;France;United States;Poland;Germany;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2015-004476-30-PT
(EUCTR)
15/06/201618/04/2016A Study to Evaluate the Efficacy of RO5459072 in Participants With Primary Sjögren’s SyndromeA MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP PHASE 2A STUDY TO ASSESS THE EFFICACY OF RO5459072 IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME Primary Sjögren’s syndrome
MedDRA version: 20.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Cathepsin S inhibitor
Product Code: RO545-9072/F03
INN or Proposed INN: Not applicable
Other descriptive name: RO5459072
F. Hoffmann-La Roche LtdNULLNot RecruitingFemale: yes
Male: yes
70Phase 2France;United States;Portugal;Poland;Germany;United Kingdom